| Novavax is a late-stage biotechnology company focused on the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Co.'s vaccine candidates, including its primary candidates, ResVax and NanoFlu, are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. Co.'s product pipeline targets a variety of infectious diseases. Co. is also developing immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. Co.'s primary adjuvant, Matrix-M, has been shown to improve immune responses and was well-tolerated in multiple clinical trials. We show 42 historical shares outstanding datapoints in our NVAX shares outstanding history coverage, used to compute NVAX market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NVAX market cap history over the course of time is important for investors
interested in comparing NVAX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NVAX versus a peer is one thing; comparing
NVAX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NVAX can fluctuate over the course of history.
With this page we aim to empower investors researching NVAX by allowing them to research the NVAX market cap history.